The fifth Core Group (CG) meeting of the Global Drug-resistant TB Initiative (GDI) took place in WHO Headquarters in Geneva, Switzerland on 8 July 2016. All members (bar 1) of the CG, attended the meeting, along with observers from the Global Laboratory Initiative (GLI), Global TB Drugs Facility (GDF), Global Fund (GF) and the GDI Task Forces.
The objectives of the meeting were:
- To follow up on recommendations made and action points agreed upon during 4th GDI CG meeting in December 2015, and subsequent monthly teleconferences;
- To provide an update on progress in scale up of MDR-TB services and care, and updates on new policies;
- To provide an update on the progress of the respective GDI Task Forces; and
- To provide an update on the progress of the GDI "Costed Framework" document.
The participants were briefed about the activities of the GDI Secretariat since the forth CG meeting held in December 2015. New WHO policy guidance on programmatic management of MDR-TB and second-line drug susceptibility testing was presented to the participants. Chairs of regional GLC presented on the MDR-TB scale-up in their respective regions. This was followed by the respective GDI Task Forces presenting their progress and the activities in their respective areas to the GDI CG. A final session was dedicated to the final steps in development of the GDI "Costed Framework" document.
The report of the meeting and action points were compiled by the secretariat, approved by the core group and shared as a public document on the GDI website.
All meeting documents can be found at the " Meetings" tab."
